Published Studies Related to Definity (Perflutren)
A pilot randomized clinical safety study of sonothrombolysis augmentation with ultrasound-activated perflutren-lipid microspheres for acute ischemic stroke. [2008.05]
BACKGROUND AND PURPOSE: Ultrasound transiently expands perflutren-lipid microspheres (muS), transmitting energy momentum to surrounding fluids. We report a pilot safety/feasibility study of ultrasound-activated muS with systemic tissue plasminogen activator (tPA)... CONCLUSIONS: Perflutren microS reached and permeated beyond intracranial occlusions with no increase in sICH after systemic thrombolysis suggesting feasibility of further microS dose-escalation studies and development of drug delivery to tissues with compromised perfusion.
Sudden death after intravenous administration of a perflutren contrast agent: a case of pseudocomplication? [2009.06]
Perflutren cardiac ultrasound agents improve diagnostic accuracy in patients whose imaging is technically difficult. This report describes a case of sudden death approximately 5 minutes after the intravenous administration of 0.5 mL of perflutren contrast agent (Definity) during transthoracic echocardiography with suboptimal baseline images performed 10 days after coronary artery bypass graft surgery because of hypotension and tachycardia in a 73-year-old patient with severe left ventricular systolic dysfunction.
Acoustic and kinetic behaviour of definity in mice exposed to high frequency ultrasound. [2009.02]
Microbubble contrast agents have shown clinical potential for characterising blood flow using 1 to 10 MHz ultrasound; however, scaling their use for similar applications in the mouse with high frequency ultrasound (20 to 60 MHz) has not been addressed... These results suggest that quantitative contrast flow studies in the mouse using high frequency ultrasound are possible for doses between 10 and 60 microL kg(-1).
The safety of deFinity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses. [2008.11]
BACKGROUND: The purpose of this retrospective analysis was to define the incidence of severe adverse events after exposure to ultrasound contrast agents... CONCLUSION: This multicenter, retrospective analysis includes the largest number of doses of ultrasound contrast agents ever published and a large number of patients evaluated in a wide variety of settings, including the critically ill. It shows that these agents have a good safety profile in both cardiac and abdominal ultrasound applications. The incidence of severe adverse reactions to ultrasound contrast agents is no greater, and may be lower, than that reported for contrast agents commonly used in other cardiac imaging tests.
Ultrasound-enhanced thrombolysis using Definity as a cavitation nucleation agent. [2008.09]
Ultrasound has been shown previously to act synergistically with a thrombolytic agent, such as recombinant tissue plasminogen activator (rt-PA) to accelerate thrombolysis. In this in vitro study, a commercial contrast agent, Definity, was used to promote and sustain the nucleation of cavitation during pulsed ultrasound exposure at 120 kHz...
Clinical Trials Related to Definity (Perflutren)
Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors [Recruiting]
The primary purpose of this study is to demonstrate the safety and effectiveness of using an
intra-operative ultrasound contrast agent(Definity®) for the identification of known liver
A Pilot Study of the Effects of Contrast Enhanced Endoscopic Ultrasound on Determining Vascular Involvement in Pancreatic Lesions [Not yet recruiting]
In the US, pancreas cancer is the fifth leading cause of cancer related deaths. It was
estimated to have taken 36,800 lives in 2010. Unfortunately, curing pancreatic cancer
requires surgical removal. Surgical removal of the pancreas is associated with high
morbidity and mortality, as well as high rates of complications. One way to aid surgeons in
removing pancreatic tumors is by providing them with a good idea of where the tumor is
located and what surrounding structures are involved. This currently happens through many
different modalities of imaging; usually computed tomography (CT) and endoscopic ultrasound.
Even with these forms of imaging (and sometimes others), surgeons will occasionally open a
patient and find that the tumor cannot be removed due to its involvement with surrounding
One way to avoid potentially unnecessary procedures or to help a surgeon navigate this
delicate procedure would be to provide more detailed information about the tumor. Several of
the techniques currently used to image the body have rapidly advanced over recent years.
Typical advancements come through better resolution of the images or contrast to enhance
desired parts of the images. Ultrasound has not seen such a two pronged advance. Ultrasound
has seen substantial advances in resolution to enhance picture quality, but contrast has not
been used clinically to assess pancreatic masses whereas it is for cardiologists to use
contrast to look at potential defects in the heart.
The contrast that is used with ultrasound is different from that of CT scans. CT scanners
use a dye that can be potentially hazardous. This dye can lead to serious kidney damage in
some patients. Ultrasound contrast, on the other hand, is made of small micro bubbles filled
with a harmless gas. Because of the way ultrasound works, these micro bubbles reflect the
sound waves differently than the surrounding tissue and thus provide contrast between normal
tissue and abnormal tissue. The contrast used in this study, Definity, and is the same
contrast used by Cardiologists.
The CE-EUS will be used for research purposes only and will not be used for any clinical
decision making. The surgeon will be blinded to the results of the research CE-EUS. The
investigators will compare the research pre-operative contrast enhanced endoscopic
ultrasounds images with already completed standard-of-care CT scans, the actual pancreatic
involvement seen in surgery and the pathology reports.
Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients [Recruiting]
The purpose of this study is to determine if Nebivolol improves microvascular perfusion in
skeletal muscle during exercise in hypertensive patients and whether this improvement is
accompanied by reduction in vascular oxidative stress or increased endothelial nitric oxide
synthase (eNOS) expression in humans.
A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery Pressure [Recruiting]
The purpose of this clinical research is to learn if DEFINITY® 416 will cause any adverse
effects during Right Heart Catheterization. This research was requested by the FDA.
Prospective Analysis and Comparison of Stress Echo to Real-Time Myocardial Contrast Stress Echo [Available]
Reports of Suspected Definity (Perflutren) Side Effects
Back Pain (6),
Atrial Fibrillation (4),
Unresponsive TO Stimuli (3),
Ejection Fraction Decreased (3),
Viith Nerve Paralysis (2),
Fatigue (2), more >>